Bioxytran, Inc. (OTCMKTS:BIXT) Short Interest Up 4,632.7% in May

Bioxytran, Inc. (OTCMKTS:BIXT) was the target of a significant increase in short interest during the month of May. As of May 15th, there was short interest totaling 14,198 shares, an increase of 4,632.7% from the April 30th total of 300 shares. Based on an average daily volume of 81,682 shares, the days-to-cover ratio is currently 0.2 days. Currently, 0.0% of the shares of the stock are sold short.

Bioxytran Price Performance

BIXT stock remained flat at $0.03 during midday trading on Wednesday. 35,617 shares of the company’s stock were exchanged, compared to its average volume of 279,913. Bioxytran has a fifty-two week low of $0.03 and a fifty-two week high of $0.16. The company has a market cap of $3.43 million, a P/E ratio of -1.50 and a beta of 1.95. The company’s 50-day moving average is $0.04 and its 200-day moving average is $0.05.

Bioxytran (OTCMKTS:BIXT) last released its quarterly earnings results on Friday, May 15th. The company reported ($0.02) EPS for the quarter.

Bioxytran Company Profile

Bioxytran, Inc is a clinical-stage biotechnology company focused on the development of synthetic oxygen carriers and novel oxygen therapeutics for acute care and chronic disease applications. The company’s proprietary platform is designed to safely deliver therapeutic levels of oxygen to hypoxic tissues, addressing conditions such as ischemia-reperfusion injury, organ transplantation, and traumatic injury. Its lead product candidates target unmet medical needs in cardiovascular and neurological disorders, wound healing, and critical care settings.

Bioxytran’s research pipeline comprises multiple preclinical-stage assets that leverage stabilized perfluorocarbon emulsions to achieve controlled oxygen release.